Anti-COVID antibody therapeutics have been developed but not widely used due to their
high cost and escape of neutralization from the emerging variants. Here, we describe the …

The SARS-CoV-2 pandemic highlights the need for a detailed molecular understanding of
protective antibody responses. This is underscored by the emergence and spread of SARS …

As global vaccination campaigns against SARS-CoV-2 proceed, there is particular interest
in the longevity of immune protection, especially with regard to increasingly infectious virus …

Chronic lymphocytic leukemia (CLL) patients have lower seroconversion rates and antibody
titers following SARS-CoV-2 vaccination, but the reasons for this diminished response are …

Abstract Introduction We evaluated the Roche Elecsys Anti-SARS-CoV-2 and Snibe SARS-
CoV-2 S-RBD IgG spike chemiluminescent immunoassays and compared them to existing …

With the exponential rise in infections by CoV-2 and the scarcity of antiviral therapeutics, the
development of an effective vaccine for the SARS CoV-2 is critical. The emerging pandemic …

Background Antibodies induced by COVID-19 vaccination have been shown to wane over
time. Current tests for assessing virus-neutralizing antibodies are complex and time …

Abstract Coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory
syndrome coronavirus 2 (SARS‐CoV‐2) infection, was first reported in Wuhan, China, in …

Аннотация Статья посвящена обзору исследований, посвященных роли антител,
цитокинов, белков комплемента, молекул основного комплекса гистосовместимости …

Background The ongoing pandemic of COVID-19, caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), poses a serious threat to global public health and …